pilsicainide has been researched along with Wolff-Parkinson-White Syndrome in 5 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT)." | 2.68 | Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia. ( Fujiki, A; Inoue, H; Tani, M; Yoshida, S, 1996) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanemoto, M | 1 |
| Shimizu, A | 1 |
| Yamagata, T | 1 |
| Esato, M | 1 |
| Ueyama, T | 1 |
| Yoshiga, Y | 1 |
| Kakugawa, H | 1 |
| Kametani, R | 1 |
| Inoue, N | 1 |
| Sawa, A | 1 |
| Matsuzaki, M | 1 |
| Fujiki, A | 2 |
| Tani, M | 1 |
| Yoshida, S | 1 |
| Inoue, H | 2 |
| Usui, M | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Hayashi, H | 2 |
| Niwano, S | 1 |
| Kitano, Y | 1 |
| Moriguchi, M | 1 |
| Izumi, T | 1 |
| Terazawa, T | 1 |
| Suzuki, M | 1 |
| Goto, T | 1 |
| Kato, R | 1 |
| Ito, A | 1 |
| Isikawa, S | 1 |
| Sotobata, I | 1 |
1 trial available for pilsicainide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Disopyramide; Electrophysiology; Female; Heart Cond | 1996 |
4 other studies available for pilsicainide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Differentiation of the electrophysiological effects on the atrial myocardium between the pure Na channel blocker, pilsicainide, and flecainide.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Flutter; Electrocardiography; Electrophysiologic Techniques, C | 2004 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography | 2000 |
Suppressive effect of SUN1165 on supraventricular tachycardia.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography | 1991 |